Study to Determine the Pharmacokinetics of a Single 14C-labeled Intravenous Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose to Postmenopausal Women With Osteopenia or Osteoporosis.

Trial Profile

Study to Determine the Pharmacokinetics of a Single 14C-labeled Intravenous Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose to Postmenopausal Women With Osteopenia or Osteoporosis.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2010

At a glance

  • Drugs Alendronic acid; Alendronic acid; Risedronic acid; Risedronic acid
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 26 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top